person Sign In / Create Account

Vaccines, COVID-19, and Myeloma with Dr. Mike Thompson

Immunotherapy (CAR T, Bispecifics and more) Treatment Chapter

Apr 07, 2021 / 04:00PM - 05:00PM EDT

Watch Recording

Event Description

Name: Vaccines, COVID-19, and Myeloma with Dr. Mike Thompson
Start: 2021-04-07T16:00:00-04:00
End: 2021-04-07T17:00:00-04:00

With new COVID-19 vaccinations, many of us within the Myeloma Community have questions about how it will affect us. Come hear from an expert, Dr. Mike Thompson, as he presents on infections, vaccines, and antibiotics for myeloma patients, then take the opportunity to ask Dr. Thompson any questions you may have.

Schedule & Agenda

Introductions

04:00PM

Audrey Burton-Bethke

Audrey introduces our featured speaker, Dr. Mike Thompson, and the event agenda.

04:00PM

Audrey Burton-Bethke

Introductions

Audrey introduces our featured speaker, Dr. Mike Thompson, and the event agenda.

Presentation

04:05PM

Dr. Mike Thompson

Dr. Thompson presents on infections, vaccines, and antibiotics for myeloma patients.

04:05PM

Dr. Mike Thompson

Presentation

Dr. Thompson presents on infections, vaccines, and antibiotics for myeloma patients.

Q&A

04:45PM

Audience

Dr. Thompson answers the audience's questions about his presentation and related topics.

04:45PM

Audience

Q&A

Dr. Thompson answers the audience's questions about his presentation and related topics.

Speakers & Moderators

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Michael A. Thompson, MD, Ph.D.

Michael A. Thompson, MD, Ph.D. is the Medical Director for the Early Phase Cancer Research Program, Patient-Centered Research at the Aurora Research Institute. He is an active clinical researcher whose interests include hematologic or blood cancers (lymphoma, myeloma, leukemia, and myelodysplastic syndrome). He is also interested in developing new treatments for all cancers, particularly early phase (Phase I and II) molecular biomarker-driven clinical trials. In addition, he is extensively published and serves as a reviewer for multiple scientific publications.

Read Bio